文献速递浆细胞疾病

解读多发性骨髓瘤中组蛋白乙酰化与染色质重塑的动态变化:超越尾部的故事

Deciphering the dynamics of histone acetylation and chromatin remodeling in multiple myeloma: a tale beyond the tails.
PubMed 文献 · Blood · 2025-01-01

本文综述了多发性骨髓瘤中组蛋白乙酰化失调及其与染色质重塑复合物的相互作用,这些表观遗传改变参与DNA修复、损伤应答、细胞存活和凋亡信号等过程,为表观遗传靶向治疗提供依据;文中还综述了靶向组蛋白去乙酰化酶(CREB结合蛋白/p300)及含溴结构域和超末端蛋白的表观遗传调节药物,并讨论其局限性与未来前景。

要点

  • 表观遗传改变在多发性骨髓瘤发生及治疗耐药中起关键作用,参与转录组不稳定和细胞适应。
  • 组蛋白修饰与染色质重塑异常影响DNA修复、损伤应答、细胞存活和凋亡信号等过程。
  • 本文综述靶向组蛋白去乙酰化酶(CREB结合蛋白/p300)及含溴结构域和超末端蛋白的表观遗传调节药物及其局限性。

核心结论

  • 组蛋白乙酰化失调及其与染色质重塑复合物的相互作用在多发性骨髓瘤中协调动态染色质功能状态和转录输出,为表观遗传靶向治疗提供依据。

研究设计与样本

  • 综述,聚焦多发性骨髓瘤中组蛋白乙酰化失调及其与染色质重塑复合物相互作用的最新进展与研究空白。

主要发现

  • 表观遗传改变导致高水平转录组不稳定,使细胞通过多样进化轨迹适应靶向治疗和免疫治疗。
  • 组蛋白修饰和染色质重塑异常影响DNA修复、DNA损伤应答、细胞存活和凋亡信号等过程。

局限性

  • 原文报告了靶向组蛋白去乙酰化酶(CREB结合蛋白/p300)及含溴结构域和超末端蛋白的表观遗传调节药物的局限性,但摘要未具体说明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of multiple myeloma is typically associated with various cytogenetic abnormalities; however, these genetic changes alone do not fully account for the observed heterogeneity in patient prognosis and treatment response. Recent studies leveraging next-generation sequencing and genomic approaches have shown that epigenetic alterations are crucial in myeloma development and therapeutic resistance. These changes contribute to high levels of transcriptomic instability and enable cellular adaptation to targeted therapies and immunotherapies through diverse evolutionary trajectories. In this regard, aberrations of histone modifications and chromatin remodeling affect various cellular processes such as DNA repair, DNA damage response, cellular survival, and apoptosis signaling, which provides a strong rationale for developing epigenetic-targeted therapies for myeloma treatment. In this review, we focus on recent advances and research gaps in understanding the deregulation of histone acetylation, a widespread and versatile process of histone modification occurring at lysine residues at the N-terminus of histone tails, and its intimate interplay with chromatin remodeling complexes in orchestrating dynamic chromatin functional states and transcriptional outputs. We also provide an updated review of epigenetic modulatory drugs targeting histone deacetylases (CREB-binding protein/p300) and bromodomain and extraterminal proteins, along with a discussion of their limitations and future perspectives in myeloma treatment.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Xiong S, Zhou J, Chng WJ, et al. Deciphering the dynamics of histone acetylation and chromatin remodeling in multiple myeloma: a tale beyond the tails. Blood. 2025. PMID: 40608868. doi:10.1182/blood.2025028403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。